Pro Medicus Ltd (ASX:PME) Reports Strong FY2024 Results
Operational Success
Pro Medicus Ltd (ASX:PME) reported a record financial performance for FY2024. Revenue increased by 29.3% to $161.5 million, with net profit after tax rising by 36.5% to $82.8 million. The company’s success is attributed to its robust technology, dedicated staff, and strong management team led by Dr. Sam Hupert.
Contract Wins and Renewals
In FY2024, Pro Medicus secured nine new contract wins in North America, including its largest contract with Baylor Scott & White, which is now fully operational. Two significant client renewals have been achieved, one in North America and one in Australia, both at increased fee levels. The company maintains a strong pipeline of new opportunities.
Financial Results and Future Outlook
The company remains cash flow positive, with liquid investments and retained cash rising from $121.5 million to $155.4 million. The board anticipates strong growth throughout FY2025, with current financial results exceeding budget forecasts. Dr. Hupert noted, “We anticipate that the second half of the financial year will be stronger than the first half.”
Dividend Increases
Pro Medicus has increased its dividend payment for FY2024 to 40 cents per share, fully franked, representing a 33% increase over the previous year. The dividend payout ratio stands at approximately 50%, funded from internally generated cash flow. Future dividends will be reviewed based on profitability and investment needs.
Investment in Growth and ESG Commitments
The board is exploring acquisition opportunities to bolster its product suite. Pro Medicus recently invested in Elucid Bioimaging Inc, enhancing its offerings in cardiac imaging. The rise in market value has increased shareholder interest in the company’s environmental, social, and governance (ESG) practices, which the board is committed to addressing effectively.
Closing Remarks
Dr. Hupert expressed gratitude towards the staff and directors for their dedication in achieving another successful year for Pro Medicus.
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.